Treat FTD Fund: Clinical trials for FTD

The Treat FTD Fund focuses on providing critical funding for early-stage clinical trials to address the unique challenges of developing treatments for frontotemporal dementia (FTD). It emphasizes the importance of:

• Building upon emerging scientific understandings of FTD's biological mechanisms.
• Stimulating new therapy developments for FTD disorders.
• Advancing biomarker development for informative trial endpoints.
• Enabling innovative trial designs and technologies. The fund supports testing drugs or devices at phase 0, 1, or 2 trials, targeting novel or repurposed drug candidates or devices worldwide. Both disease-modifying and symptomatic approaches are considered acceptable, with an emphasis on sound scientific rationale and effective clinical trial designs. The goal is to de-risk clinical development programs, producing data for clear decision-making and attracting subsequent funding. Awards can reach up to $2,000,000 depending on trial stage and scope, encouraging co-funding for additional support.